tbuckley/cabot-search huggingface dataset:
NIMG-35. QUANTITATIVE ESTIMATION OF PROGRESSION-FREE SURVIVAL BASED ON RADIOMICS ANALYSIS OF PREOPERATIVE MULTI-PARAMETRIC MRI IN PATIENTS WITH GLIOBLASTOMA
Authors: Anahita Fathi Kazerooni, Saima Rathore, Hamed Akbari, Jeffrey Rudie, Chiharu Sako, Sung Min Ha, Elizabeth Mamourian, Spyridon Bakas, Gaurav Shukla, Michel Bilello, Christos Davatzikos
Journal: Neuro-Oncology (2019)

Abstract PURPOSE Glioblastoma managed with maximal resection and adjuvant chemoradiation has large heterogeneity at the time of tumor recurrence (progression-free survival, PFS). Upfront identification of patients with shorter than median PFS, may facilitate better personalization of treatment, such as patient stratification into clinical trials for treatment intensification and/or supportive care. The aim of the current study was to build a radiomics model that can reliably predict PFS in patients with glioblastoma at the time of initial diagnosis. EXPERIMENTAL DESIGN: A total of 66 de novo glioblastoma patients in a single institution who underwent gross total resection followed by standard adjuvant chemoradiation, were found to have pathologically confirmed recurrence. Patients who had sufficient follow-up MRI to reliably determine PFS and available pre-surgical multi-parametric MRI (mpMRI) (T1, T1Gd, T2, T2-FLAIR, DTI, DSC-MR images) were included. The patients were stratified into two classes of “short PFS (≤7 months, n=35)” and “long PFS (≥9 months, n=19)”. An extensive set of features was extracted from preoperative mpMRI scans, including shape and volumetric measures computed for different tumorous regions, and characteristics derived from histograms and gray-level co-occurrence matrix (GLCM). Predictive modeling for discrimination of patients with short from those with long PFS was performed using a 10-fold cross-validated support vector machine classifier. RESULTS An accuracy of 79.6% was achieved for prediction of short and long PFS (sensitivity=83%, specificity=74%, AUC=0.86 [95%CI: 0.76–0.96]; short-PSF was considered the positive class). The patients with shorter PFS showed markedly higher cell density in the nonenhancing tumor (DTI), higher neo-angiogenesis in the enhancing tumor (DSC-MRI, T1Gd), lower water concentration in the enhancing tumor region (T2), and higher maximum enhancement (calculated by the subtraction of T1 from T1Gd) in the edema region. CONCLUSION Quantitative assessment of preoperative mpMRI provides accurate prediction of PFS for patients with glioblastoma, which can aid in personalized treatment planning.
Surgery of the Anus, Rectum, and Colon
Authors: N MORTENSEN
Journal: Gut (2001)

Surgery of the Anus, Rectum, and Colon , 2nd edn, vols 1 and 2. Edited by M R B Keighley, N S Williams (Pp 2702; illustrated; £285). UK: Harcourt Publishers Ltd, 2000. ISBN 0702023353.

This is a monumental effort and the editors, who have written much of this textbook themselves, are to be congratulated on a terrific job. They have taken on the task of reworking the iconic textbook first started by the late and great John Goligher. His was a very personal style, with repeated references to his own practice and results, and then a weighing of the evidence and a firm opinion, an approach which was much loved. With the growing emphasis on a larger body of evidence, the editors have widened their search in …
Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL
Authors: Jing Pan, Shiyu Zuo, Biping Deng, Xiuwen Xu, Chuo Li, Qinlong Zheng, Zhuojun Ling, Weiliang Song, Jinlong Xu, Jiajia Duan, Zelin Wang, Xinjian Yu, Alex H. Chang, Xiaoming Feng, Chunrong Tong
Journal: Blood (2019)
Altered Megakaryocytes Are Associated with Development of Pulmonary Fibrosis in Mice Carrying the Hypomorphic Gata1low Mutation
Authors: Barbara Bacci, Francesca Gobbo, Mariana Roccaro, Angelo Peli, Maria Zingariello, Fabrizio Martelli, Paola Verachi, Claudio Bardelli, Maria Mazzarini, Giuseppe Sarli, Anna Rita Migliaccio
Journal: Blood (2019)
Improving the quality of surveillance colonoscopy in inflammatory bowel disease
Authors: Marietta Iacucci, Rosanna Cannatelli, Gian Eugenio Tontini, Remo Panaccione, Silvio Danese, Gionata Fiorino, Takayuki Matsumoto, Gursimran S Kochhar, Bo Shen, Ralf Kiesslich, Subrata Ghosh
Journal: The Lancet. Gastroenterology & hepatology (2019)
Urine Proteomic Analysis Reveals Disease-Specific Patterns in Pediatric Patients with Classical Hodgkin's Disease(HD). an Addon Study to the Euronet-PHL-C2 Trial
Authors: Karl-Walter Sykora, Jochen Metzger, Dieter Körholz, Michael Frühwald, Gabriele Strauss, Norbert Jorch, Jozef Zlocha, Thomas Wiesel, Axel Sauerbrey, Monika Streiter, Rhoikos Furtwaengler, Gunnar Cario, Thorsten Simon, Holger Christiansen, Peter Vorwerk, Angela Wawer, Wolfram Scheurlen, Hermann Müller, Stefan Bielack, Martin Ebinger, Klaus-Michael Debatin, Oliver Andres, Christine Mauz-Körholz, Anja Troeger, Dominik Schneider, Eva M Weissinger
Journal: Blood (2019)
Constitutively Activated STAT3 Induces the Expression of Gli1 in Chronic Lymphocytic Leukemia Cells
Authors: Uri Rozovski, David M. Harris, Ping Li, Zhiming Liu, Taghi Manshouri, Ivo Veletic, Preetesh Jain, Alessandra Ferrajoli, Jan A. Burger, Prithviraj Bose, Philip A. Thompson, Nitin Jain, Srdan Verstovsek, William G. Wierda, Michael J Keating, Zeev E. Estrov
Journal: Blood (2019)
Validation of SIE, Sies, GITMO Operational Criteria for the Definition of Fitness in Elderly Patients Affected with Acute Myeloid Leukemia: A Six-Years Retrospective Real-Life Experience
Authors: Raffaele Palmieri, Giovangiacinto Paterno, Eleonora De Bellis, Elisa Buzzatti, Valentina Rossi, Ambra Di Veroli, Fabiana Esposito, Lisa Mercante, Carmelo Gurnari, Paola Casciani, Maria Ilaria Del Principe, Luca Maurillo, Maria Teresa Voso, William Arcese, Adriano Venditti, Francesco Buccisano
Journal: Blood (2019)
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial
Authors: Daniel P Petrylak, Ronald de Wit, Kim N Chi, Alexandra Drakaki, Cora N Sternberg, Hiroyuki Nishiyama, Daniel Castellano, Syed A Hussain, Aude Fléchon, Aristotelis Bamias, Evan Y Yu, Michiel S van der Heijden, Nobuaki Matsubara, Boris Alekseev, Andrea Necchi, Lajos Géczi, Yen-Chuan Ou, Hasan Senol Coskun, Wen-Pin Su, Jens Bedke, Georgios Gakis, Ivor J Percent, Jae-Lyun Lee, Marcello Tucci, Andrey Semenov, Fredrik Laestadius, Avivit Peer, Giampaolo Tortora, Sufia Safina, Xavier Garcia del Muro, Alejo Rodriguez-Vida, Irfan Cicin, Hakan Harputluoglu, Scott T Tagawa, Ulka Vaishampayan, Jeanny B Aragon-Ching, Oday Hamid, Astra M Liepa, Sameera Wijayawardana, Francesca Russo, Richard A Walgren, Annamaria H Zimmermann, Rebecca R Hozak, Katherine M Bell-McGuinn, Thomas Powles, Suet-Lai Shirley Wong, Thean Hsiang Tan, Elizabeth Jane Hovey, Timothy Dudley Clay, Siobhan Su Wan Ng, Annemie Rutten, Jean-Pascal Machiels, Herlinde Dumez, Susanna Yee-Shan Cheng, Cristiano Ferrario, Lisa Sengeloev, Niels Viggo Jensen, Constance Thibault, Brigitte Laguerre, Florence Joly, Stéphane Culine, Catherine Becht, Günter Niegisch, Michael Stöckle, Marc-Oliver Grimm, Christina A Schwentner, Wolfgang Schultze-Seemann, Haralambos Kalofonos, Dimitrios Mavroudis, Christos Papandreou, Vasilis Karavasilis, Janos Révész, Eli Rosenbaum, Raya Leibowitz-Amit, Daniel Kejzman, David Sarid, Giorgio Vittorio Scagliotti, Sergio Bracarda, Francesco Massari, Takahiro Osawa, Naoto Miyajima, Nobuo Shinohara, Fumimasa Fukuta, Chikara Ohyama, Wataru Obara, Shinichi Yamashita, Yoshihiko Tomita, Koji Kawai, Satoshi Fukasawa, Masafumi Oyama, Junji Yonese, Masayoshi Nagata, Motohide Uemura, Kazuo Nishimura, Mutsushi Kawakita, Hiroyuki Tsunemori, Katsuyoshi Hashine, Junichi Inokuchi, Akira Yokomizo, Satoshi Nagamori, Hyo Jin Lee, Se Hoon Park, Sun Young Rha, Yu Jung Kim, Yun-Gyoo Lee, Leticia Vazquez Cortés, Claudia Lorena Urzua Flores, Reinoud J.B. Blaisse, Fransiscus L.G. Erdkamp, Maureen J.B. Aarts, Joanna Wojcik-Tomaszewska, Piotr Tomczak, Bozena Sikora-Kupis, Michael Schenker, Alina Amalia Herzal, Anghel Adrian Udrea, Petr Karlov, Roman Fomkin, Pablo Gajate Borau, Enrique Grande, Juan Ignacio Delgado Mignorance, Yu-Li Su, Jian-Ri Li, Chien-Liang Lin, Chia-Chi Lin, Su-Peng Yeh, Mustafa Erman, Yuksel Urun, Yuriy Golovko, Igor Bondarenko, Ivan Sinielnikov, Simon J. Crabb, Isabel Syndikus, Robert Huddart, Santhanam Sundar, Simon Chowdhury, Naveed Sarwar, Thomas W. Flaig, Chong Xian Pan, James K. Schwarz, Jennifer Lyn Cultrera, Peter Istvan Acs, John D. Hainsworth, Benjamin T. Herms, William Eyre Lawler, Thomas Eugene Lowe
Journal: The Lancet Oncology (2019)
The Prognostic Significance of Monocytopenia in Patients with Myelodysplastic Syndrome
Authors: Panagiotis T Diamantopoulos, Vassiliki Pappa, Nora-Athina Viniou, Ioannis Kotsianidis, Alexandra Kourakli, Argiris Symeonidis, Sotirios Papageorgiou, Elena E. Solomou, Anastasia Pouli, Panagiotis Panagiotidis, Maria Dimou, Kalliopi Zafeiropoulou, Stamatis J. Karakatsanis, Anna Vardi, Theodoros P. Vassilakopoulos, Dimitrios Tsokanas, George Drakos, Spyros Hontropoulos, Eleftheria Hatzimichael, Aikaterini Megalakaki, Panagiotis Repousis, Maria Kotsopoulou, Georgia Kaiafa, Menelaos Konstantinos Papoutselis, Anastasia Sioni, Nikolaos Charchalakis, Eleni Bouronikou, Georgios Vasilopoulos, Vasileios Lazaris, Maria Spiliotopoulou, Flora Kontopidou, Christos K. Kontos, Stamatina Kalyva, Apostolos Hatzitolios, Helen A. Papadaki, Achilles Anagnostopoulos, Nikolaos Anagnostopoulos, Athanasios Galanopoulos
Journal: Blood (2019)
Bright spots, physical activity investments that (almost) worked: Carrot Rewards app, driving engagement with pennies a day
Authors: Renante Rondina II, Emma K Pearson, Harry Prapavessis, Lauren White, Sarah Richard, Marc S Mitchell
Journal: British Journal of Sports Medicine (2019)

Carrot Rewards was a free smartphone app developed by Carrot Insights as part of a public–private partnership with the Public Health Agency of Canada to reward Canadians for engaging in healthy behaviours (ie, walking).1 In 2015, as part of the government of Canada’s Multi-Sectoral Partnership Approach to Healthy Living and Chronic Disease Prevention, $C5 million of seed funding was invested over 4 years to support app development and user acquisition.1 The majority of the investment was used to reward Canadians to download the app. The app was discontinued in June 2019 due, in part, to a lack of long-term funding from regional (eg, provincial/territorial) governments.2

The app was launched in March 2016. In June 2019, it was available in the Canadian provinces of British Columbia, Ontario and Newfoundland and Labrador, as well as the Northwest Territories. At that time, over one million Canadians had completed app registration. Carrot Rewards’ users were not exposed to direct advertising; rather, the app employed a ‘sponsored-content’ model whereby strategic partners (eg, provincial/territorial ministries of health) could use the platform to promote healthy living. Carrot Insights profited by placing a mark-up on the rewards that were paid for by strategic partners and subsequently issued to users who completed healthy living activities.

The Carrot Rewards cornerstone feature, the Steps walking programme (figure 1), yielded promising results.3 Users who met individualised daily step goals were rewarded with loyalty points worth $C0.04/day, which could be redeemed for consumer goods such as movies or groceries. Though small, rewards were tied to objectively assessed behaviours and were provided instantaneously using smartphone technology (eg, …
Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance
Authors: Silpa Narayanan, Chao-Yun Cai, Yehuda G. Assaraf, Hui-Qin Guo, Qingbin Cui, Liuya Wei, Juan-Juan Huang, Charles R. Ashby, Zhe-Sheng Chen
Journal: Drug Resistance Updates (2019)
Pharmacokinetics of Nilotinib in Pediatric Patients with Philadelphia Chromosome–Positive Chronic Myeloid Leukemia or Acute Lymphoblastic Leukemia
Authors: Nobuko Hijiya, C. Michel Zwaan, Carmelo Rizzari, Robin Foà, Floor Abbink, Donna Lancaster, Judith Landman-Parker, Frédéric Millot, John Moppett, Brigitte Nelken, Maria Caterina Putti, Xianbin Tian, Karen Sinclair, Helene Santanastasio, Aby Buchbinder, Pamela Kearns
Journal: Clinical Cancer Research (2019)

Abstract Purpose: We investigated nilotinib exposure in pediatric patients with chronic myeloid leukemia (CML) or Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL) resistant to, relapsed on, refractory to, or intolerant of previous treatment. Patients and Methods: Fifteen patients (aged 1–&amp;lt;18 years) with CML resistant to or intolerant of imatinib and/or dasatinib (n = 11) or Ph+ ALL relapsed on or refractory to standard therapy (n = 4) enrolled in this phase I study. Nilotinib (230 mg/m2 twice daily; equivalent to the adult 400-mg twice-daily dose) was administered orally in 12 or 24 cycles of 28 days. The primary objective was to characterize the pharmacokinetics of nilotinib in pediatric patients. Results: The area under the concentration–time curve at steady state was slightly lower in pediatric patients versus adults (14,751.4 vs. 17,102.9 ng/h/mL); the geometric mean ratio (GMR; pediatric:adult) was 0.86 [90% confidence interval (CI), 0.70–1.06]. Body surface area–adjusted systemic clearance was slightly higher in pediatric versus adult patients (GMR, 1.30; 90% CI, 1.04–1.62). Nilotinib was generally well tolerated. The most common adverse events were headache, vomiting, increased blood bilirubin, and rash. Three patients with CML achieved major molecular response, and three with Ph+ ALL achieved complete remission. Conclusions: Nilotinib 230 mg/m2 twice daily in pediatric patients provided a pharmacokinetics and safety profile comparable with the adult reference dose; clinical activity was demonstrated in both CML and Ph+ ALL. This dose is recommended for further evaluation in pediatric patients. The safety profile was consistent with that in adults.
A Randomized Trial of EPOCH-Based Chemotherapy with Vorinostat for Highly Aggressive HIV-Associated Lymphomas: Updated Results Evaluating Impact of Diagnosis-to-Treatment Interval (DTI) and Pre-Protocol Systemic Therapy on Outcomes
Authors: Juan Carlos Ramos, Joseph Sparano, Page C. Moore, Eric Siegel, Jeannette Y Lee, Erin G. Reid, Richard F. Ambinder, Amy Chadburn, Paul G. Rubinstein, Christine Durand, Ethel Cesarman, Lee Ratner, Robert A Baiocchi, David M. Aboulafia, Lawrence D Kaplan, Adam Capoferri, Ronald T. Mitsuyasu, Ariela Noy
Journal: Blood (2019)
PRMT5 Inhibition Drives Therapeutic Vulnerability to BCL-2 Inhibition with Venetoclax and Provides Rationale for Combination Therapy in Mantle Cell Lymphoma
Authors: Fiona Brown, Yang Zhang, Claire Hinterschied, Alexander Prouty, Shelby Sloan, JoBeth Helmig-Mason, Ji Hyun Chung, Kris Vaddi, Selina Chen-Kiang, Maurizio Di Liberto, Lapo Alinari, Peggy Scherle, Rosa Lapalombella, Jihye Paik, Robert A Baiocchi
Journal: Blood (2019)
Results of Intercontinental Cooperative Non-Hodgkin T-Cell Lymphoma Prospective Registry Study
Authors: Sang Eun Yoon, Seok Jin Kim, Tsai-Yun Chen, Yong Park, Li Mei Poon, Young Rok Do, Ho Sup Lee, Won Sik Lee, Hong-ghi Lee, Soon Thye Lim, Hye Jin Kang, Cosphiadi Irawan, Jae Joon Han, Hyo Jung Kim, Cheolwon Suh, Hwan Jung Yun, Soo Chin Ng, Jae-Cheol Jo, Byeong Seok Sohn, Sung Yong Oh, Yeung-Chul Mun, Daryl Tan, Seong Kyu Park, Jae-Yong Kwak, Ye Guo, Huilai Zhang, Jun Zhu, Weili Zhao, Won Seog Kim
Journal: Blood (2019)
Positivity Rates of Tests Used at Immune Thrombocytopenia Diagnosis to Detect Associated Diseases. a Prospective Multicenter Cohort Study of 218 Patients
Authors: Guillaume Moulis, Thibault Comont, Johanne Germain, Anaïs Essilini, Natacha Brun, Claire Dingremont, Brice Castel, Philippe Montané de la Roque, Serge Madaule, Laurent Sailler, Laurent Prudhomme, Sophie Arista, Laurent Balardy, Francis Gaches, Benjamin Hebraud, Cecile Borel, Stéphane Sire, Miguel Carreiro, Guillaume Martin-Blondel, Laurent Alric, Patrick Giraud, Maryse Lapeyre-Mestre, Odile Beyne-Rauzy, Daniel Adoue
Journal: Blood (2016)
IgM-Gammopathies Transformed into Aggressive Lymphoma: Incidence, Basal Clinical Features and Outcome of a Registry Based, Spanish Retrospective Series
Authors: Irene Dogliotti, Cristina Jiménez, Federica Cavallo, Noemi Puig, Gian Maria Zaccaria, Veronica Gonzalez De La Calle, Maria Eugenia Sarasquete, Miguel Alcoceba, Pilar Delgado, Maria Rosa López, Aránzazu García Mateo, Simone Ferrero, Mario Boccadoro, Marcos González, Ramón García-Sanz
Journal: Blood (2019)
Heterogeneous 68Ga–Prostate-Specific Membrane Antigen Uptake in the Left Upper Abdomen
Authors: Ayça Arçay, Funda Aydin, Ömer Kutlu, Güzide Ayşe Ocak, Firat Güngör
Journal: Clinical Nuclear Medicine (2019)

Abstract A 50-year-old man with recently diagnosed prostate adenocarcinoma was referred for whole-body 68 Ga–prostate-specific membrane antigen (PSMA) PET/CT scan for staging. Apart from some nonspecific findings, 68 Ga-PSMA PET/CT revealed large soft tissue mass in the left upper abdomen showing heterogeneous tracer uptake. Histological examination of the mass was interpreted as gastrointestinal/extragastrointestinal stromal tumor by pathologists. Prostate-specific membrane antigen is considered specific for prostate cancer cells, although PSMA activity has been described in many other benign or malign conditions. That is why PSMA uptake in uncommon locations for prostate cancer metastasis must be considered for second malignancies or other benign conditions.
Allogeneic Hematopoietic Stem Cell Transplantation in Patients of 65 Years or Older: A Monocenter Analysis on 252 Patients
Authors: Samia Harbi, Raynier Devillier, Sabine Furst, Luca Castagna, Angela Granata, Faezeh Legrand, Thomas Pagliardini, Valerio Maisano, Christian Chabannon, Jean Elcheikh, Colombe Saillard, Marie Anne Hospital, Evelyne D'Incan, Catalina Montes De Oca, Nawel Belmecheri, Catherine Faucher, Claude Lemarie, Boris Calmels, Djamel Mokart, Cecile Braticevic, Maud Cecile, Reda Bouabdallah, Norbert Vey, Didier Blaise
Journal: Blood (2019)
Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer
Authors: Daniel C. Danila, Russell Z. Szmulewitz, Ulka Vaishampayan, Celestia S. Higano, Ari D. Baron, Houston N. Gilbert, Flavia Brunstein, Marija Milojic-Blair, Bei Wang, Omar Kabbarah, Michael Mamounas, Bernard M. Fine, Daniel J. Maslyar, Alexander Ungewickell, Howard I. Scher
Journal: Journal of Clinical Oncology (2019)

Six-transmembrane epithelial antigen of the prostate 1 (STEAP1) is highly expressed in prostate cancers. DSTP3086S is a humanized immunoglobulin G1 anti-STEAP1 monoclonal antibody linked to the potent antimitotic agent monomethyl auristatin E. This study evaluated the safety and activity of DSTP3086S in patients with metastatic castration-resistant prostate cancer.Patients were enrolled in a 3 + 3 dose escalation study to evaluate DSTP3086S (0.3 to 2.8 mg/kg intravenously) given once every 3 weeks followed by cohort expansion at the recommended phase II dose or weekly (0.8 to 1.0 mg/kg).Seventy-seven patients were given DSTP3086S once every 3 weeks, and seven were treated weekly. Two patients in the once-every-3-weeks dose escalation had dose-limiting grade 3 transaminitis. Grade 3 hyperglycemia and grade 4 hypophosphatemia were dose-limiting toxicities in one patient treated at 1.0 mg/kg weekly. Initial cohort expansion evaluated dosing at 2.8 mg/kg once every 3 weeks (n = 10), but frequent dose reductions led to testing of 2.4 mg/kg (n = 39) in the expansion phase. Common related adverse events (> 20%) across doses (once every 3 weeks) were fatigue, peripheral neuropathy, nausea, constipation, anorexia, diarrhea, and vomiting. DSTP3086S pharmacokinetics were linear. Among 62 patients who received > 2 mg/kg DSTP3086S once every 3 weeks, 11 (18%) demonstrated a ≥ 50% decline in prostate-specific antigen; two (6%) of 36 with measurable disease at baseline achieved a radiographic partial response; and of 27 patients with informative unfavorable baseline circulating tumor cells ≥ 5/7.5 mL of blood, 16 (59%) showed conversions to favorable circulating tumor cells < 5. No prostate-specific antigen or RECIST responses were seen with weekly dosing.DSTP3086S has acceptable safety at the recommended phase II dose level of 2.4 mg/kg once every 3 weeks. Antitumor activity at doses between 2.25 and 2.8 mg/kg once every 3 weeks supports the potential benefit of treating STEAP1-expressing metastatic castration-resistant prostate cancer with an STEAP1-targeting antibody-drug conjugate.
A support programme for secondary prevention in patients with transient ischaemic attack and minor stroke (INSPiRE-TMS): an open-label, randomised controlled trial
Authors: Michael Ahmadi, Inga Laumeier, Thomas Ihl, Maureen Steinicke, Caroline Ferse, Matthias Endres, Armin Grau, Sidsel Hastrup, Holger Poppert, Frederick Palm, Martin Schoene, Christian L Seifert, Farid I Kandil, Joachim E Weber, Paul von Weitzel-Mudersbach, Martin L J Wimmer, Ale Algra, Pierre Amarenco, Jacoba P Greving, Otto Busse, Friedrich Köhler, Peter Marx, Heinrich J Audebert
Journal: The Lancet Neurology (2019)
Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Naïve Patients with Relapsed or Refractory Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Multi-Center Phase 1, Two-Arm, Dose-Escalation Study
Authors: Jacqueline S Garcia, Lillian Werner, Benjamin K. Tomlinson, Michael Keng, Myrna Nahas, Andrew Brunner, Samer K. Khaled, Alexandra Savell, Marlise Luskin, David P. Steensma, Martha Wadleigh, Eric S. Winer, Edwin P. Alyea, Corey Cutler, Vincent T. Ho, Donna S Neuberg, Nicole Cullen, Andreas Kantartzis, Ana Lako, Scott Rodig, R. Coleman Lindsley, Yael Flamand, Claire Manuszak, Ryan Brennick, Mariano Severgnini, Stephanie Andrews, Ilene Galinsky, Pavan Bachireddy, Yohei Arihara, Jerome Ritz, Matthew S. Davids, Howard Streicher, Catherine J. Wu, Richard M. Stone, Daniel J. DeAngelo, Robert J. Soiffer
Journal: Blood (2019)
Treatment of Diabetes
Authors: Robert B. Flinn
Journal: JAMA (1972)

To the Editor.—  Although the initial furor which greeted the University Group Diabetes Program (UGDP) has somewhat subsided, it is our opinion that the study, valid or invalid (and we certainly do not wish to revive that brouhaha) quite usefully serves to remind clinicians of the desirability of reevaluating, at intervals, the continuing need for any medicine which patients have been taking for a long time.  We have requested the attending physicians in our diabetes clinic to evaluate the effects of discontinuation of hypoglycemic agents taken orally in all of their patients receiving those agents alone, ie, without insulin as additional therapy. During the study period, we make no effort to reinforce dietary prescription. The patients' blood sugar levels, while they were taking medication, are available to us for at least six months, and in many instances over several years or more, to compare with their blood sugar levels while
Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study
Authors: Constantine S. Tam, Tanya Siddiqi, John N. Allan, Thomas J. Kipps, Ian W. Flinn, Bryone J. Kuss, Stephen Opat, Paul M. Barr, Alessandra Tedeschi, Ryan Jacobs, Xavier C. Badoux, Paolo Ghia, Juthamas Sukbuntherng, Ahmed Hamed Salem, Kristin Russell, Karl Eckert, Cathy Zhou, Joi Ninomoto, Danelle F. James, William G. Wierda
Journal: Blood (2019)
Ezh1 Inhibits Commitment to Hemogenic Fate and HSPC Formation during Vertebrate Development
Authors: Rebecca Soto, Edroaldo Lummertz da rocha, Linda T Vo, Mariam Hachimi, Jenna M Frame, Paul J. Wrighton, Wolfram Goessling, George Q. Daley, Trista E North
Journal: Blood (2019)